Treatment of restless leg syndrome with pergolide--an open clinical trial.
Identifieur interne : 004405 ( PubMed/Corpus ); précédent : 004404; suivant : 004406Treatment of restless leg syndrome with pergolide--an open clinical trial.
Auteurs : J. Winkelmann ; T C Wetter ; K. Stiasny ; W H Oertel ; C. TrenkwalderSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Domperidone (adverse effects), Domperidone (therapeutic use), Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Pergolide (adverse effects), Pergolide (therapeutic use), Restless Legs Syndrome (drug therapy), Restless Legs Syndrome (etiology), Restless Legs Syndrome (genetics), Treatment Outcome.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Domperidone, Levodopa, Pergolide.
- chemical , therapeutic use : Antiparkinson Agents, Domperidone, Levodopa, Pergolide.
- drug therapy : Restless Legs Syndrome.
- etiology : Restless Legs Syndrome.
- genetics : Restless Legs Syndrome.
- Aged, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
Dopaminergic treatment with levodopa (L-dopa) has been proven as the treatment of first choice in patients with restless leg syndrome (RLS). Augmentation of symptoms and end-of-dose rebound phenomena under L-dopa/decarboxylase inhibitor treatment present major problems in some patients. To evaluate the efficacy of pergolide in RLS, we treated 15 patients suffering from severe RLS, who had previously experienced an augmentation of symptoms under long-term treatment with L-dopa, in an open clinical trial with pergolide. All patients reported an improvement of their RLS symptoms. Our study shows that pergolide, if administered at a mean dose of 0.4 mg in combination with domperidone, is a very effective drug in the treatment of sleep disturbances and daytime symptoms associated with RLS, and does not cause any serious side effects during the observation period of 6 months.
DOI: 10.1002/mds.870130333
PubMed: 9613756
Links to Exploration step
pubmed:9613756Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of restless leg syndrome with pergolide--an open clinical trial.</title><author><name sortKey="Winkelmann, J" sort="Winkelmann, J" uniqKey="Winkelmann J" first="J" last="Winkelmann">J. Winkelmann</name><affiliation><nlm:affiliation>Max Planck Institute of Psychiatry, Clinical Institute, Neurology, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Wetter, T C" sort="Wetter, T C" uniqKey="Wetter T" first="T C" last="Wetter">T C Wetter</name></author><author><name sortKey="Stiasny, K" sort="Stiasny, K" uniqKey="Stiasny K" first="K" last="Stiasny">K. Stiasny</name></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name></author><author><name sortKey="Trenkwalder, C" sort="Trenkwalder, C" uniqKey="Trenkwalder C" first="C" last="Trenkwalder">C. Trenkwalder</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9613756</idno><idno type="pmid">9613756</idno><idno type="doi">10.1002/mds.870130333</idno><idno type="wicri:Area/PubMed/Corpus">004405</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of restless leg syndrome with pergolide--an open clinical trial.</title><author><name sortKey="Winkelmann, J" sort="Winkelmann, J" uniqKey="Winkelmann J" first="J" last="Winkelmann">J. Winkelmann</name><affiliation><nlm:affiliation>Max Planck Institute of Psychiatry, Clinical Institute, Neurology, Munich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Wetter, T C" sort="Wetter, T C" uniqKey="Wetter T" first="T C" last="Wetter">T C Wetter</name></author><author><name sortKey="Stiasny, K" sort="Stiasny, K" uniqKey="Stiasny K" first="K" last="Stiasny">K. Stiasny</name></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name></author><author><name sortKey="Trenkwalder, C" sort="Trenkwalder, C" uniqKey="Trenkwalder C" first="C" last="Trenkwalder">C. Trenkwalder</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Domperidone (adverse effects)</term><term>Domperidone (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Pergolide (adverse effects)</term><term>Pergolide (therapeutic use)</term><term>Restless Legs Syndrome (drug therapy)</term><term>Restless Legs Syndrome (etiology)</term><term>Restless Legs Syndrome (genetics)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Domperidone</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Domperidone</term><term>Levodopa</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopaminergic treatment with levodopa (L-dopa) has been proven as the treatment of first choice in patients with restless leg syndrome (RLS). Augmentation of symptoms and end-of-dose rebound phenomena under L-dopa/decarboxylase inhibitor treatment present major problems in some patients. To evaluate the efficacy of pergolide in RLS, we treated 15 patients suffering from severe RLS, who had previously experienced an augmentation of symptoms under long-term treatment with L-dopa, in an open clinical trial with pergolide. All patients reported an improvement of their RLS symptoms. Our study shows that pergolide, if administered at a mean dose of 0.4 mg in combination with domperidone, is a very effective drug in the treatment of sleep disturbances and daytime symptoms associated with RLS, and does not cause any serious side effects during the observation period of 6 months.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9613756</PMID><DateCreated><Year>1998</Year><Month>08</Month><Day>10</Day></DateCreated><DateCompleted><Year>1998</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>1998</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Treatment of restless leg syndrome with pergolide--an open clinical trial.</ArticleTitle><Pagination><MedlinePgn>566-9</MedlinePgn></Pagination><Abstract><AbstractText>Dopaminergic treatment with levodopa (L-dopa) has been proven as the treatment of first choice in patients with restless leg syndrome (RLS). Augmentation of symptoms and end-of-dose rebound phenomena under L-dopa/decarboxylase inhibitor treatment present major problems in some patients. To evaluate the efficacy of pergolide in RLS, we treated 15 patients suffering from severe RLS, who had previously experienced an augmentation of symptoms under long-term treatment with L-dopa, in an open clinical trial with pergolide. All patients reported an improvement of their RLS symptoms. Our study shows that pergolide, if administered at a mean dose of 0.4 mg in combination with domperidone, is a very effective drug in the treatment of sleep disturbances and daytime symptoms associated with RLS, and does not cause any serious side effects during the observation period of 6 months.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winkelmann</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, Clinical Institute, Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetter</LastName><ForeName>T C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Stiasny</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Oertel</LastName><ForeName>W H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Trenkwalder</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>24MJ822NZ9</RegistryNumber><NameOfSubstance UI="D010479">Pergolide</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>5587267Z69</RegistryNumber><NameOfSubstance UI="D004294">Domperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004294">Domperidone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010479">Pergolide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012148">Restless Legs Syndrome</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9613756</ArticleId><ArticleId IdType="doi">10.1002/mds.870130333</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004405 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004405 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:9613756
|texte= Treatment of restless leg syndrome with pergolide--an open clinical trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9613756" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |